Angelina Jolie’s public journey with breast cancer risk assessment and preventative surgery has significantly influenced global awareness of the BRCA1 gene mutation. In 2013, the actor revealed she underwent a prophylactic double mastectomy after learning she carried a mutation that gave her an estimated 87% risk of developing breast cancer. Her decision, documented in a New York Times essay, prompted a documented surge in genetic testing rates known as the "Angelina Effect."
Understanding the BRCA1 Mutation and Cancer Risk
The BRCA1 and BRCA2 genes are human genes that produce proteins responsible for repairing damaged DNA. According to the National Cancer Institute, when these genes mutate, they no longer function correctly, which significantly increases the likelihood of developing specific cancers.
For women, a harmful BRCA1 mutation increases the cumulative risk of developing breast cancer to between 55% and 72% by age 80. The risk for ovarian cancer similarly rises to between 39% and 44%. Jolie’s family history—which included the death of her mother, Marcheline Bertrand, from ovarian cancer at age 56—was a primary factor in her decision to pursue genetic counseling and testing.
The Impact of the "Angelina Effect"
Jolie’s disclosure triggered a measurable change in clinical practice and patient behavior. A study published in the journal Breast Cancer Research and Treatment analyzed the impact of her announcement on genetic testing referrals. Researchers found that in the weeks following her May 2013 announcement, BRCA testing referrals increased by approximately 2.5 times in the United Kingdom compared to the same period in previous years.
This phenomenon, termed the "Angelina Effect" by researchers, demonstrated how high-profile public health disclosures can drive medical engagement. However, the surge also highlighted challenges, including the need for adequate genetic counseling to ensure patients understand the difference between population-level risk and individual genetic profiles.
Clinical Guidelines for Genetic Testing
Not every individual with a family history of cancer requires BRCA testing. The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians perform a detailed family history assessment to identify candidates for referral to a genetic counselor.
Testing is generally indicated for individuals with:
- A personal or family history of breast cancer diagnosed at age 50 or younger.
- Multiple primary breast cancers in the same individual.
- A family history of ovarian, fallopian tube, or primary peritoneal cancer.
- A known BRCA mutation in a family member.
Proactive Management Options
For those who test positive for a BRCA mutation, medical management typically focuses on three strategies: increased surveillance, chemoprevention, and risk-reducing surgery.
- Enhanced Surveillance: This includes more frequent clinical breast exams and annual breast MRI screenings starting at a younger age than the general population.
- Chemoprevention: The use of medications such as tamoxifen or raloxifene may reduce the risk of breast cancer in high-risk individuals.
- Risk-Reducing Surgery: Prophylactic mastectomy and prophylactic salpingo-oophorectomy (removal of ovaries and fallopian tubes) are the most definitive options for risk reduction. According to the American Cancer Society, these surgeries can reduce breast cancer risk by 90% or more and significantly lower the risk of ovarian cancer.
Patients are encouraged to discuss these options with a multidisciplinary team, including oncologists, genetic counselors, and surgeons, to create a personalized care plan based on their specific mutation and life stage.
Related reading